Drugs

FDA alerts health care professionals, patients, and the drug supply chain not to use stolen fertility drugs, Gonal-f RFF Redi-ject and Gonal-f Multi-Dose

[5/30/2018] FDA is alerting health care professionals, patients, and the drug supply chain of stolen injectable fertility medications, Gonal-f RFF Redi-ject (follitropin alfa injection) and Gonal-f Multi-Dose (follitropin alfa injection). Patients who have product with the lot numbers below should not use them.

All product with these lot numbers were in this stolen shipment. The lot numbers are located on the flap of each box, below the tamper-proof seal and next to the 2D barcode:

Product nameNDC LotExpirationDosage form
Gonal-f RFF Redi-ject 450 IU (0.75 mL)44087-1116-1BA0491375/31/2019Liquid for injection
Gonal-f Multi-Dose 1050 IU44087-9070-1BA0490379/30/2019Vial powder with diluent for injection
Gonal-f Multi-Dose 450 IU44087-9030-1BA049143 2/29/2020Vial powder with diluent for injection
Gonal-f Multi-Dose 450 IU44087-9030-1BA049040 9/30/2019Vial powder with diluent for injection

These products were stolen in Italy on May 17, 2018, and were intended to be shipped to the United States. EMD Serono Inc. of Rockland, Massachusetts, reported the theft of more than 16,000 packages of Gonal-f RFF Redi-ject and Gonal-f Multi-Dose to FDA on May 18, 2018.

Drug supply chain stakeholders that receive or possess these lot numbers must notify FDA via Form FDA 3911. Anyone who has received suspicious or unsolicited offers to purchase Gonal-f products since May 17, 2018, should contact FDA Office of Criminal Investigations at 800-551-3989. 

Drug supply chain stakeholders should continue to remain vigilant when buying or selling Gonal-f and check the lot number to prevent stolen product from entering the drug supply chain.

Patients, health care professionals, and drug supply chain stakeholders should check the product and label for signs of tampering before using. FDA also reminds health care professionals, patients, and drug supply chain stakeholders to purchase products only from licensed wholesale distributors and pharmacies. See FDA’s Know Your Source and BeSafeRx programs for more information.

FDA encourages health care professionals and patients to report adverse reactions or quality problems with any human drug products to FDA’s MedWatch Adverse Event Reporting program:

Lot/Batch# BA049137 

Lot/Batch# BA049137

Lot/Batch# BA049037  

Lot/Batch#  BA049037

Lot/Batch# BA049143 

Lot/Batch#  BA049143

Lot/Batch# BA049040 

Lot/Batch# BA049040

Page Last Updated: 05/31/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English